• Harrow highlighted new clinical and real-world evidence for IHEEZO and BYOOVIZ presented at the ASRS 2026 annual meeting.
• Interim results from a randomized study suggested IHEEZO could improve post-injection comfort and overall patient experience versus a common anesthetic approach.
• A large retrospective review found no signal that IHEEZO’s gel formulation increased infection risk when used with a chlorhexidine-based antisepsis routine.
• The QUELL randomized, multi-center trial remains ongoing, with topline results expected in Q4 2026.
• Interim findings from a large real-world post-marketing surveillance study of BYOOVIZ were also presented at the meeting.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Harrow Inc. published the original content used to generate this news brief on July 20, 2026, and is solely responsible for the information contained therein.